SCHEMBL5073554

SCHEMBL5073554

CC(=O)C(C#N)c1cc(Cl)cc(Cl)c1Cl

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.35
HPGD P15428 1/20 0.34
TSHR P16473 1/20 0.34
HSD17B10 Q99714 1/20 0.34
GABRA1 P14867 8/20 0.34
GABRG2 P18507 7/20 0.34
GABRB3 P28472 7/20 0.34
GABRB2 P47870 4/20 0.34
GABRB1 P18505 3/20 0.33
LMNA P02545 1/20 0.31
POLB P06746 1/20 0.31
GAA P10253 1/20 0.31
RAPGEF3 O95398 1/20 0.31
RAPGEF4 Q8WZA2 1/20 0.31
SCN9A Q15858 1/20 0.31
SCN2A Q99250 1/20 0.31
SCN3A Q9NY46 1/20 0.31
SCN10A Q9Y5Y9 1/20 0.31
AHR P35869 1/20 0.31
FSCN1 Q16658 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5070766 0.80 HPGD (0.34) ALDH1A1HPGDLMNAGAARAPGEF3
SCHEMBL6049469 0.80 ALDH1A1 (0.47) ALDH1A1GABRA1GABRG2GABRB3GABRB2
SCHEMBL5073551 0.80 ALDH1A1 (0.32) ALDH1A1HPGDTSHRHSD17B10RAPGEF3
SCHEMBL7282534 0.77 RAPGEF3 (0.35) ALDH1A1HPGDHSD17B10GABRA1GABRG2
SCHEMBL6049547 0.75 BRD4 (0.36) ALDH1A1TSHRGABRA1GABRG2GABRB3
SCHEMBL9739531 0.72 ALDH1A1 (0.44) ALDH1A1GAA
SCHEMBL5729444 0.72 TSHR (0.35) TSHRLMNAGAARAPGEF3RAPGEF4
SCHEMBL15018895 0.72 AKR1C4 (0.33) TSHRGABRA1GABRG2GABRB3GABRB2
SCHEMBL157185 0.71 MDM2 (0.41) ALDH1A1HPGDLMNA
SCHEMBL30211225 0.71 MDM2 (0.41) ALDH1A1HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1325916-B1 Piperazinyl-substituted phenyl pyrimidine derivatives useful in the treatment or prevention of disorders of the central nervous system WELLCOME FOUND (GB) 2008-01-23 EP disclosed
EP-1681058-A2 Pharmacologically active cns compounds THE WELLCOME FOUNDATION LIMITED (GB) 2006-07-19 EP disclosed
EP-1325916-A1 Piperazinyl-substituted phenyl pyrimidine derivatives useful in the treatment or prevention of disorders of the central nervous system THE WELLCOME FOUNDATION LIMITED (GB) 2003-07-09 EP disclosed
US-5712276-A TREATING NERVOUS SYSTEM DISORDERS GLAXO WELLCOME INC. (US) 1998-01-27 US disclosed
US-5684005-A PHENYLPYRIMIDINE COMPOUNDS AS INHIBITORS OF EXCITATORY AMINO ACID GLUTAMATE GLAXO WELLCOME INC. (US) 1997-11-04 US disclosed
US-5635507-A PIPERAZINYL PHENYLPYRIMIDINE COMPOUND TREATING BRAIN DISORDER GLAXO WELLCOME INC. (US) 1997-06-03 US disclosed
US-5597827-A CENTRAL NERVOUS SYSTEM DISORDERS AND ANTIISCHEMIC AGENTS GLAXO WELLCOME INC. 1997-01-28 US disclosed
US-5597828-A TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS CEREBRAL ISCHEMIC DAMAGE AND EPILEPSY GLAXO WELLCOME INC. (US) 1997-01-28 US disclosed
US-5591746-A GLUTAMATE INHIBITORS; CENTRAL NERVOUS SYSTEM DISORDERS GLAXO WELLCOME INC. 1997-01-07 US disclosed
US-5587380-A ANTIISCHEMIC AGENTS GLAXO WELLCOME INC. (US) 1996-12-24 US disclosed
EP-0727213-A2 Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders THE WELLCOME FOUNDATION LIMITED (GB) 1996-08-21 EP disclosed
EP-0727214-A2 Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders THE WELLCOME FOUNDATION LIMITED (GB) 1996-08-21 EP disclosed
EP-0727212-A2 Substituted phenylpyrimidine derivatives, useful in the treatment of prevention of CNS disorders THE WELLCOME FOUNDATION LIMITED (GB) 1996-08-21 EP disclosed
EP-0715851-A2 Substituted phenylpyrimidine derivatives, useful in the treatment of prevention of CNS disorders THE WELLCOME FOUNDATION LIMITED (GB) 1996-06-12 EP disclosed
EP-0713703-A2 Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders THE WELLCOME FOUNDATION LIMITED (GB) 1996-05-29 EP disclosed
CN-1117046-A Method for preparing pharmaceutically active CNS compounds WELLCOME FOUND (GB) 1996-02-21 CN disclosed
CN-1113487-A Method for preparing pharmaceutically active CNS compounds WELLCOME FOUND (GB) 1995-12-20 CN disclosed
US-5136080-A Intermediates for glutamate inhibitors BURROUGHS WELLCOME CO. (US) 1992-08-04 US disclosed
CN-1052306-A Compounds having pharmacological activity on the central nervous system WELLCOME FOUND (GB) 1991-06-19 CN disclosed
EP-0372934-A2 Pharmacologically active CNS compounds THE WELLCOME FOUNDATION LIMITED (GB) 1990-06-13 EP disclosed